Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.

Irvin MR, Sitlani CM, Floyd JS, Psaty BM, Bis JC, Wiggins KL, Whitsel EA, Sturmer T, Stewart J, Raffield L, Sun F, Liu CT, Xu H, Cupples AL, Tanner RM, Rossing P, Smith A, Zilhão NR, Launer LJ, Noordam R, Rotter JI, Yao J, Li X, Guo X, Limdi N, Sundaresan A, Lange L, Correa A, Stott DJ, Ford I, Jukema JW, Gudnason V, Mook-Kanamori DO, Trompet S, Palmas W, Warren HR, Hellwege JN, Giri A, O'donnell C, Hung AM, Edwards TL, Ahluwalia TS, Arnett DK, Avery CL
Am J Hypertens. 2019 32 (12): 1146-1153

PMID: 31545351 · PMCID: PMC6856621 · DOI:10.1093/ajh/hpz150

MeSH Terms (29)

African Americans Aged Antihypertensive Agents Blood Pressure Case-Control Studies DNA (Cytosine-5-)-Methyltransferases DNA-Binding Proteins DNA Methyltransferase 3A Drug Resistance Dystrophin-Associated Proteins Europe Female Genetic Loci Genome-Wide Association Study Humans Hypertension Male Middle Aged Myosin Heavy Chains Myosin Type V Neuropeptides Pharmacogenetics Pharmacogenomic Variants Polymorphism, Single Nucleotide Risk Assessment Risk Factors Transcription Factors United States Whites

Connections (1)

This publication is referenced by other Labnodes entities:

Links